Tools
White Dot Syndromes
Introduction
The white dot syndromes constitute a group of inflammatory chorioretinopathies. The common, defining clinical feature is the presence of multiple, discrete, white lesions located at the deeper levels of the retina choroid.[1] Several of the white dot syndromes are associated with a viral prodrome, and an etiology is lacking for these conditions. Typically seen in young, otherwise healthy adults, the white dot syndromes most often present with symptoms of photopsia, floaters, decreased night vision, blurred vision, and visual field loss.[2] These conditions can be acute in onset or transient without long-term visual consequence. White dot syndromes share many similar clinical features, including the "tell-tale" chorioretinal lesions, several distinct clinical features, and diagnostic testing findings that allow for additional characterization. Commonly recognized white dot syndromes include: Multiple evanescent white dot syndrome (MEWDS), acute retinal pigment epitheliopathy (ARPE), acute posterior multifocal placoid pigment epitheliopathy (APMPPE), multifocal choroiditis and panuveitis (MCP), acute zonal occult outer retinopathy (AZOOR), birdshot chorioretinopathy, serpiginous choroidopathy, and punctate inner choroidopathy (PIC).[1] These conditions are conventionally recognized as distinct identities, and some suggest that they represent a spectrum of chorioretinal disease.[3]
Etiology
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Etiology
The etiology of the white dot syndromes remains unknown. Several entities are associated with a viral prodrome, suggesting a potential viral or infectious etiology. Similar to most autoimmune conditions, an unknown trigger is thought to precipitate an inflammatory or autoimmune process in the posterior eye.[4] The white dot syndromes represent a primary ocular process and are not associated with systemic inflammatory or autoimmune disease. An increased prevalence of such conditions has been demonstrated in several subgroups of patients with white dot syndrome (i.e., AZOOR).[5] Birdshot chorioretinopathy is highly associated with the presence of the HLA-A29 haplotype.[6] This correlation is so prominent that the absence of this haplotype, even within the presence of typical clinical features, should prompt consideration of an alternative diagnosis.
Epidemiology
With a few exceptions (birdshot chorioretinopathy, serpiginous choroiditis), white dot syndromes present in young, otherwise healthy, adults below the age of 50.[1] Gender differences allow for further characterization of these entities, with a female predominance recognized in birdshot chorioretinopathy, MCP, PIC, AZOOR, and MEWDS.[2] The incidence of white dot syndromes in a community-based population was 0.45 per 100,000 per year, consistent with their description as rare disease entities.[7]
History and Physical
Historical features most consistent with a white dot syndrome include the relatively acute onset of visual symptoms, including visual field loss or scotoma, flashes of light or photopsia, blurred vision, and floaters.[2] Consistent with a potential viral or infectious etiology, patients may report symptoms of a viral prodrome. The primary feature involves developing characteristic white or cream-colored chorioretinal lesions, the morphology and distribution of which aid in distinguishing white dot syndrome from others. White dot syndromes may differ in the laterality of involvement, with some conditions typically presenting in a unilateral fashion (MEWDS), others are bilateral (APMPPE, birdshot chorioretinopathy, MCP).[1] The presence of anterior chamber cell or inflammation is rare, except for MCP. Vitritis may be seen in several white dot syndromes; it is most consistently seen in birdshot chorioretinopathy.[8]
Evaluation
Laboratory testing in patients with a white dot syndrome is generally most useful in excluding alternative etiologies on the differential diagnosis.[9][10][11] Serologic testing for syphilis is recommended in all patients, with screening for tuberculosis conducted in those patients with known exposure or risks. A poor screening test, angiotensin-converting enzyme (ACE) levels are often obtained in conjunction with chest x-ray imaging to evaluate for evidence of underlying sarcoidosis.[12] Ocular diagnostic testing may assist in the differentiation of specific white dot syndromes with suggestive features often evident on fluorescein angiography (FA), optical coherence tomography (OCT), visual field testing, indocyanine green (ICG) angiography, fundus autofluorescence, and electroretinography (ERG) studies.[13][14][15][16]
Treatment / Management
Many of the white dot syndromes are benign and self-limited, negating the need for treatment. A few white dot syndromes are persistent and progressive, with significant visual consequences if untreated (MCP, serpiginous choroiditis, and birdshot chorioretinopathy). Treatment in these conditions initially involves using local or systemic corticosteroids with a transition to steroid-sparing systemic immunotherapy.[17][18] Typical agents would include traditional immunotherapies such as methotrexate, mycophenolate mofetil, azathioprine, cyclosporine, as well as biological agents, including anti-TNF medications: adalimumab and infliximab.[19] In vision-threatening conditions such as serpiginous choroiditis, the cytotoxic agents cyclophosphamide and chlorambucil have been utilized.[20] Management of associated ocular complications such as cystoid macular edema (CME) and choroidal neovascularization (CNV) may involve immunosuppression or localized ocular therapies to include anti-vascular endothelial growth factor (VEGF) agents, laser photocoagulation therapy, or photodynamic therapy.[21][22][23] (B2)
Differential Diagnosis
Both infectious and noninfectious entities are included in the differential diagnosis of the white dot syndromes. The noninfectious processes include sarcoidosis, Vogt-Koyanagi-Harada (VKH) syndrome, sympathetic ophthalmia, and intraocular lymphoma.[11] Syphilis, primary ocular histoplasmosis syndrome (POHS), tuberculosis, and diffuse unilateral subacute neuroretinitis (DUSN) are infectious entities that should be considered in the differential diagnosis of white dot syndrome.[24]
Prognosis
The prognosis for most white dot syndromes (ARPE, MEWDS, APMPPE, AZOOR) is good, with most patients experiencing a benign and self-limited course with an eventual return to or near baseline vision.[25][26][27][26] The persistence of various visual phenomena, such as scotoma and photopsia, may occur in a small percentage of such patients.[26] Several white dot syndromes (MCP, birdshot chorioretinopathy, serpiginous choroiditis) demonstrate a more persistent and progressive clinical course and may result in moderate to severe visual decrement.[28][29][30][28] Early identification and management of these conditions are, therefore, of paramount importance.
Complications
Extraocular complications of white dot syndromes are rare. Patients may present with a viral prodrome that is typically self-limiting. In patients with APMPPE, symptoms of a viral prodrome may include meningeal features.[31] A few of the white dot syndromes are associated with autoimmune disease, so carefully evaluate for symptoms or signs that might suggest such a condition.[4] Potential complications related to the use of systemic immunotherapy require monitoring by a specialist trained in the use of such agents.[19]
Associated ocular complications include those inherent to chorioretinopathy, such as cystoid macular edema (CME) and choroidal neovascularization (CNV). The development of choroidal neovascular membranes is a prominent complication seen in patients with PIC, with estimates of 40% to 75% in some cases series.[32] Ocular complications related to the use of topical, periocular, and intravitreal corticosteroids would include premature cataract formation and increased intraocular pressure, as well as those related to procedural or surgical management.[33][34]
Deterrence and Patient Education
As stated previously, most white dot syndromes are self-limiting, and therefore no treatment is generally necessary. The clinician may want to closely monitor the condition for a month using dilated funduscopic examinations.
Pearls and Other Issues
A detailed review of individual white dot syndromes is beyond the scope of this article. The following pearls highlight several key distinguishing clinical features of several of the white dot syndromes.[1][2]
- Multiple evanescent white dot syndrome (MEWDS): young patients (age 20 to 50 years), women > men, often viral prodrome, typically unilateral, good visual prognosis, small white dots in the outer retina, “wreath-like” pattern of hyperfluorescence on FA[27][35]
- Acute retinal pigment epitheliitis (ARPE): young patients (age 10 to 30 years), women = men, most often unilateral, small hyperpigmented lesions, excellent visual prognosis[25]
- Acute posterior multifocal placoid pigment epitheliopathy (APMPPE): young patients (age 20 to 30 years), women = men, typically bilateral, flat gray or white placoid lesions at the level of the retinal pigment epithelium (RPE) and inner choroid, good visual prognosis[26]
- Acute zonal occult outer retinopathy (AZOOR): young patients, often myopic, women > men, typically bilateral (though asymmetric), initially normal-appearing fundus followed by zonal RPE atrophy and pigmentary changes, no clear benefit from treatment, good visual prognosis, though may progress or recur[36]
- Multifocal choroiditis and panuveitis (MCP): young to middle-age patients (age 20 to 60 years), women > men, bilateral, presence of anterior chamber and vitreous inflammation along with multiple yellow-white chorioretinal lesions with subsequent atrophy and scarring, complicated by CME and CNV, poor visual prognosis, treatment generally required[37]
- Birdshot chorioretinopathy: middle-aged patients (age 40 to 60 years), women > men, bilateral, difficulty with night vision, multiple cream-colored lesions in a birdshot style, radiating pattern nasally predominant, associated vitritis, CME, and retinal vasculitis, highly correlated with the presence of HLA-A29, “quenching” on FA, guarded visual prognosis, treatment generally required[30]
- Serpiginous choroiditis: middle-aged patients (age 30 to 60 years), men > women, bilateral (asymmetric), the geographic pattern of chorioretinal scarring, guarded to poor prognosis, treatment may require alkylating agents[29]
- Punctate inner choroidopathy (PIC): young patients (under 40 years of age), women > men, bilateral, small punctate gray or yellow lesions in the posterior pole evolve to atrophic scars, absence of vitritis, associated with CNV, good visual prognosis though more guarded with the development of CNV[32]
Enhancing Healthcare Team Outcomes
Thankfully, many white dot syndromes are self-limited and do not require treatment. Still, exceptions exist, and, in these circumstances, treatment often involves the use of systemic immunosuppressive therapy. Coordination of care between an ophthalmologist specializing in chorioretinal disease and a rheumatologist is often needed for optimal care. Consideration should be given to case conferences or joint clinics to facilitate such coordination.[38] An interprofessional healthcare team coordinating between the patient's family clinician, ophthalmology specialists, and nursing staff will lead to optimal results through accurate diagnosis, patient education, and in some instances, based on the particular variant, active intervention. [Level 5]
The views expressed are those of the author and do not reflect the official policy of the Department of the Army, the Department of Defense, or the U.S. Government.
References
Quillen DA, Davis JB, Gottlieb JL, Blodi BA, Callanan DG, Chang TS, Equi RA. The white dot syndromes. American journal of ophthalmology. 2004 Mar:137(3):538-50 [PubMed PMID: 15013878]
Crawford CM, Igboeli O. A review of the inflammatory chorioretinopathies: the white dot syndromes. ISRN inflammation. 2013:2013():783190. doi: 10.1155/2013/783190. Epub 2013 Oct 31 [PubMed PMID: 24294536]
Gass JD. Are acute zonal occult outer retinopathy and the white spot syndromes (AZOOR complex) specific autoimmune diseases? American journal of ophthalmology. 2003 Mar:135(3):380-1 [PubMed PMID: 12614758]
Jampol LM, Becker KG. White spot syndromes of the retina: a hypothesis based on the common genetic hypothesis of autoimmune/inflammatory disease. American journal of ophthalmology. 2003 Mar:135(3):376-9 [PubMed PMID: 12614757]
Gass JD, Agarwal A, Scott IU. Acute zonal occult outer retinopathy: a long-term follow-up study. American journal of ophthalmology. 2002 Sep:134(3):329-39 [PubMed PMID: 12208243]
Level 2 (mid-level) evidenceLeHoang P, Ozdemir N, Benhamou A, Tabary T, Edelson C, Betuel H, Semiglia R, Cohen JH. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. American journal of ophthalmology. 1992 Jan 15:113(1):33-5 [PubMed PMID: 1728143]
Abu-Yaghi NE, Hartono SP, Hodge DO, Pulido JS, Bakri SJ. White dot syndromes: a 20-year study of incidence, clinical features, and outcomes. Ocular immunology and inflammation. 2011 Dec:19(6):426-30. doi: 10.3109/09273948.2011.624287. Epub [PubMed PMID: 22106911]
Level 2 (mid-level) evidenceGass JD. Vitiliginous chorioretinitis. Archives of ophthalmology (Chicago, Ill. : 1960). 1981 Oct:99(10):1778-87 [PubMed PMID: 7295126]
Becker MD, Rosenbaum JT. Essential laboratory tests in uveitis. Developments in ophthalmology. 1999:31():92-108 [PubMed PMID: 10641202]
Lee CS,Randhawa S,Lee AY,Lam DL,Van Gelder RN, Patterns of Laboratory Testing Utilization Among Uveitis Specialists. American journal of ophthalmology. 2016 Oct; [PubMed PMID: 27521608]
Palejwala NV, Sawhney G, Raecker M, Flaxel CJ, Yeh S. The Value of Diagnostic Work-Up in the Evaluation of White Dot Syndromes. Ophthalmic surgery, lasers & imaging retina. 2017 Jul 1:48(7):540-545. doi: 10.3928/23258160-20170630-04. Epub [PubMed PMID: 28728181]
Herbort CP, Rao NA, Mochizuki M, members of Scientific Committee of First International Workshop on Ocular Sarcoidosis. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocular immunology and inflammation. 2009 May-Jun:17(3):160-9. doi: 10.1080/09273940902818861. Epub [PubMed PMID: 19585358]
Koizumi H, Pozzoni MC, Spaide RF. Fundus autofluorescence in birdshot chorioretinopathy. Ophthalmology. 2008 May:115(5):e15-20. doi: 10.1016/j.ophtha.2008.01.025. Epub 2008 Apr 18 [PubMed PMID: 18378316]
Level 2 (mid-level) evidenceVance SK, Khan S, Klancnik JM, Freund KB. Characteristic spectral-domain optical coherence tomography findings of multifocal choroiditis. Retina (Philadelphia, Pa.). 2011 Apr:31(4):717-23. doi: 10.1097/IAE.0b013e318203c1ef. Epub [PubMed PMID: 21386760]
Level 3 (low-level) evidenceDhaliwal RS, Maguire AM, Flower RW, Arribas NP. Acute posterior multifocal placoid pigment epitheliopathy. An indocyanine green angiographic study. Retina (Philadelphia, Pa.). 1993:13(4):317-25 [PubMed PMID: 8115733]
Level 3 (low-level) evidenceSieving PA, Fishman GA, Jampol LM, Pugh D. Multiple evanescent white dot syndrome. II. Electrophysiology of the photoreceptors during retinal pigment epithelial disease. Archives of ophthalmology (Chicago, Ill. : 1960). 1984 May:102(5):675-9 [PubMed PMID: 6721750]
Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Archives of ophthalmology (Chicago, Ill. : 1960). 2001 Sep:119(9):1380-3 [PubMed PMID: 11545651]
Level 3 (low-level) evidenceLevinson RD, Gonzales CR. Birdshot retinochoroidopathy: immunopathogenesis, evaluation, and treatment. Ophthalmology clinics of North America. 2002 Sep:15(3):343-50, vii [PubMed PMID: 12434483]
Jabs DA. Immunosuppression for the Uveitides. Ophthalmology. 2018 Feb:125(2):193-202. doi: 10.1016/j.ophtha.2017.08.007. Epub 2017 Sep 20 [PubMed PMID: 28942074]
Akpek EK, Jabs DA, Tessler HH, Joondeph BC, Foster CS. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology. 2002 Aug:109(8):1506-13 [PubMed PMID: 12153803]
Level 3 (low-level) evidenceRouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina (Philadelphia, Pa.). 2011 May:31(5):871-9. doi: 10.1097/IAE.0b013e3182003ca8. Epub [PubMed PMID: 21358461]
Level 2 (mid-level) evidenceShantha JG, Ho VY, Patel P, Forooghian F, Yeh S. Choroidal Neovascularization Associated With Birdshot Chorioretinopathy. Ophthalmic surgery, lasers & imaging retina. 2016 May 1:47(5):450-7. doi: 10.3928/23258160-20160419-08. Epub [PubMed PMID: 27183549]
Spaide RF, Freund KB, Slakter J, Sorenson J, Yannuzzi LA, Fisher Y. Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina (Philadelphia, Pa.). 2002 Oct:22(5):545-9 [PubMed PMID: 12441718]
Level 2 (mid-level) evidenceDreyer RF, Gass DJ. Multifocal choroiditis and panuveitis. A syndrome that mimics ocular histoplasmosis. Archives of ophthalmology (Chicago, Ill. : 1960). 1984 Dec:102(12):1776-84 [PubMed PMID: 6508619]
Level 2 (mid-level) evidenceKrill AE, Deutman AF. Acute retinal pigment epitheliitus. American journal of ophthalmology. 1972 Aug:74(2):193-205 [PubMed PMID: 5054230]
Fiore T, Iaccheri B, Androudi S, Papadaki TG, Anzaar F, Brazitikos P, D'Amico DJ, Foster CS. Acute posterior multifocal placoid pigment epitheliopathy: outcome and visual prognosis. Retina (Philadelphia, Pa.). 2009 Jul-Aug:29(7):994-1001. doi: 10.1097/IAE.0b013e3181a0bd15. Epub [PubMed PMID: 19491729]
Hangai M, Fujimoto M, Yoshimura N. Features and function of multiple evanescent white dot syndrome. Archives of ophthalmology (Chicago, Ill. : 1960). 2009 Oct:127(10):1307-13. doi: 10.1001/archophthalmol.2009.250. Epub [PubMed PMID: 19822847]
Michel SS, Ekong A, Baltatzis S, Foster CS. Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology. 2002 Feb:109(2):378-83 [PubMed PMID: 11825826]
Level 3 (low-level) evidenceNazari Khanamiri H, Rao NA. Serpiginous choroiditis and infectious multifocal serpiginoid choroiditis. Survey of ophthalmology. 2013 May-Jun:58(3):203-32. doi: 10.1016/j.survophthal.2012.08.008. Epub 2013 Mar 27 [PubMed PMID: 23541041]
Level 3 (low-level) evidenceThorne JE, Jabs DA, Peters GB, Hair D, Dunn JP, Kempen JH. Birdshot retinochoroidopathy: ocular complications and visual impairment. American journal of ophthalmology. 2005 Jul:140(1):45-51 [PubMed PMID: 16038650]
Level 2 (mid-level) evidenceWilson CA, Choromokos EA, Sheppard R. Acute posterior multifocal placoid pigment epitheliopathy and cerebral vasculitis. Archives of ophthalmology (Chicago, Ill. : 1960). 1988 Jun:106(6):796-800 [PubMed PMID: 3370009]
Level 3 (low-level) evidenceLeung TG, Moradi A, Liu D, Nguyen QD, Dunn JP, Burkholder B, Butler NJ, Ostheimer T, Thorne JE. Clinical features and incidence rate of ocular complications in punctate inner choroidopathy. Retina (Philadelphia, Pa.). 2014 Aug:34(8):1666-74. doi: 10.1097/IAE.0000000000000125. Epub [PubMed PMID: 24743642]
Level 2 (mid-level) evidenceTaylor SR, Isa H, Joshi L, Lightman S. New developments in corticosteroid therapy for uveitis. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2010:224 Suppl 1():46-53. doi: 10.1159/000318021. Epub 2010 Aug 18 [PubMed PMID: 20714181]
Sallam A, Taylor SR, Lightman S. Review and update of intraocular therapy in noninfectious uveitis. Current opinion in ophthalmology. 2011 Nov:22(6):517-22. doi: 10.1097/ICU.0b013e32834bbd68. Epub [PubMed PMID: 21897242]
Level 3 (low-level) evidenceThomas BJ, Albini TA, Flynn HW Jr. Multiple evanescent white dot syndrome: multimodal imaging and correlation with proposed pathophysiology. Ophthalmic surgery, lasers & imaging retina. 2013 Nov 1:44(6):584-7. doi: 10.3928/23258160-20131015-03. Epub 2013 Oct 24 [PubMed PMID: 24144177]
Level 3 (low-level) evidenceMonson DM, Smith JR. Acute zonal occult outer retinopathy. Survey of ophthalmology. 2011 Jan-Feb:56(1):23-35. doi: 10.1016/j.survophthal.2010.07.004. Epub 2010 Nov 5 [PubMed PMID: 21056448]
Level 3 (low-level) evidenceThorne JE, Wittenberg S, Jabs DA, Peters GB, Reed TL, Kedhar SR, Dunn JP. Multifocal choroiditis with panuveitis incidence of ocular complications and of loss of visual acuity. Ophthalmology. 2006 Dec:113(12):2310-6 [PubMed PMID: 16996607]
Level 2 (mid-level) evidenceRosenbaum JT, Dick AD. The Eyes Have it: A Rheumatologist's View of Uveitis. Arthritis & rheumatology (Hoboken, N.J.). 2018 Oct:70(10):1533-1543. doi: 10.1002/art.40568. Epub 2018 Aug 23 [PubMed PMID: 29790291]